Skip Navigation

Cardiovascular Research 2002 55(2):320-328; doi:10.1016/S0008-6363(02)00415-7
© 2002 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yuan, Z.
Right arrow Articles by Sasayama, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yuan, Z.
Right arrow Articles by Sasayama, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2002, European Society of Cardiology

Temocapril treatment ameliorates autoimmune myocarditis associated with enhanced cardiomyocyte thioredoxin expression

Zuyi Yuana, Chiharu Kishimotoa,*, Keisuke Shiojia, Hajime Nakamurab, Junji Yodoib and Shigekake Sasayamaa

aDepartment of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Kawaracho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
bDepartment of Biological Responses, Institute for Virus Research, Kyoto University, 54 Kawaracho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

* Corresponding author. Tel.: +81-75-751-3197; fax: +81-75-724-2495 kkishi{at}kuhp.kyoto-u.ac.jp

Objective: Thioredoxin (TRX) is a redox regulatory protein that protects cells from various stresses. Angiotensin-converting enzyme (ACE) inhibitor was reported to enhance endogenous antioxidant enzyme activities. This study was carried out to investigate whether temocapril, a novel non-sulfhydryl-containing ACE inhibitor, reduces the severity of myocarditis via redox regulation mechanisms involving TRX. Methods and Results: In normal rat myocytes in vitro and in vivo, Western blot showed that temocapril enhanced cytosolic redox regulatory protein TRX expression, but that neither mitochondrial TRX2 nor antioxidant enzymes, such as copper–zinc superoxide dismutase (Cu/Zn-SOD) or manganese superoxide dismutase (Mn-SOD) expression, was up-regulated by the preconditioning treatment. In rats with experimental autoimmune myocarditis (EAM), the severity of myocarditis and the protein carbonyl contents were less increased in temocapril treatment (10 mg/kg/day, orally) from day 1 to day 21, but not in temocapril treatment from day 15 to day 21. An immunohistochemical study showed that TRX stain was enhanced in infiltrating inflammatory cells and in damaged myocytes. Considering the characteristics of this model that myocardial inflammation begins around day 15 and increases until day 21, temocapril treatment for 3 weeks might be thought of as a preconditioning treatment. Conclusions: The results suggest that TRX and the redox state modified by TRX may play a crucial role in the pathophysiology of EAM. Temocapril ameliorates myocarditis associated with inducing TRX up-regulation in a preconditioning manner, although the mechanism of TRX up-regulation by temocapril remains to be elucidated.

KEYWORDS ACE inhibitors; Free radicals; Infection/inflammation; Myocarditis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
A. Sato, Y. Hoshino, T. Hara, S. Muro, H. Nakamura, M. Mishima, and J. Yodoi
Thioredoxin-1 Ameliorates Cigarette Smoke-Induced Lung Inflammation and Emphysema in Mice
J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 380 - 388.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
Y. Hoshino, T. Nakamura, A. Sato, M. Mishima, J. Yodoi, and H. Nakamura
Neurotropin Demonstrates Cytoprotective Effects in Lung Cells through the Induction of Thioredoxin-1
Am. J. Respir. Cell Mol. Biol., October 1, 2007; 37(4): 438 - 446.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
M. Kobayashi-Miura, K. Shioji, Y. Hoshino, H. Masutani, H. Nakamura, and J. Yodoi
Oxygen sensing and redox signaling: the role of thioredoxin in embryonic development and cardiac diseases
Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2040 - H2050.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
M. Nimata, T.-a. Okabe, M. Hattori, Z. Yuan, K. Shioji, and C. Kishimoto
MCI-186 (edaravone), a novel free radical scavenger, protects against acute autoimmune myocarditis in rats
Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2514 - H2518.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
Z. Yuan, Y. Liu, Y. Liu, J. Zhang, C. Kishimoto, Y. Wang, A. Ma, and Z. Liu
Peroxisome proliferation-activated receptor-{gamma} ligands ameliorate experimental autoimmune myocarditis
Cardiovasc Res, September 1, 2003; 59(3): 685 - 694.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. M. Godsel, J. S. Leon, K. Wang, J. L. Fornek, A. Molteni, and D. M. Engman
Captopril Prevents Experimental Autoimmune Myocarditis
J. Immunol., July 1, 2003; 171(1): 346 - 352.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.